Geode Capital Management
SMMT icon

Geode Capital Management’s Summit Therapeutics SMMT Stock Holding History

Geode Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50M Buy
3,427,263
+111,409
+3% +$1.98M ﹤0.01% 1628
2026
Q1 		$62.9M Buy
3,315,854
+168,374
+5% +$2.72M ﹤0.01% 1369
2025
Q4 		$55.1M Buy
3,147,480
+14,745
+0.5% +$277K ﹤0.01% 1419
2025
Q3 		$64.7M Buy
3,132,735
+197,920
+7% +$4.8M ﹤0.01% 1331
2025
Q2 		$62.5M Sell
2,934,815
-350,067
-11% -$7.98M ﹤0.01% 1307
2025
Q1 		$63.4M Buy
3,284,882
+84,035
+3% +$1.69M 0.01% 1235
2024
Q4 		$57.1M Buy
3,200,847
+101,039
+3% +$1.96M ﹤0.01% 1347
2024
Q3 		$67.9M Buy
3,099,808
+135,981
+5% +$1.9M 0.01% 1243
2024
Q2 		$23.1M Sell
2,963,827
-188,563
-6% -$1.02M ﹤0.01% 1851
2024
Q1 		$13.1M Buy
3,152,390
+66,724
+2% +$265K ﹤0.01% 2160
2023
Q4 		$8.05M Buy
3,085,666
+128,603
+4% +$265K ﹤0.01% 2453
2023
Q3 		$5.53M Buy
2,957,063
+277,754
+10% +$530K ﹤0.01% 2585
2023
Q2 		$6.73M Buy
2,679,309
+1,590,328
+146% +$2.9M ﹤0.01% 2535
2023
Q1 		$1.91M Buy
1,088,981
+617,308
+131% +$1.68M ﹤0.01% 3051
2022
Q4 		$2M Buy
471,673
+147,381
+45% +$268K ﹤0.01% 3037
2022
Q3 		$385K Buy
324,292
+269,937
+497% +$305K ﹤0.01% 3867
2022
Q2 		$54K Sell
54,355
-202,701
-79% -$284K ﹤0.01% 4758
2022
Q1 		$629K Buy
257,056
+8,235
+3% +$20.8K ﹤0.01% 3829
2021
Q4 		$669K Sell
248,821
-2,665
-1% -$12.8K ﹤0.01% 3899
2021
Q3 		$1.26M Buy
251,486
+29,893
+13% +$215K ﹤0.01% 3567
2021
Q2 		$1.65M Buy
221,593
+176,378
+390% +$1.16M ﹤0.01% 3346
2021
Q1 		$265K Buy
45,215
+25,804
+133% +$166K ﹤0.01% 4027
2020
Q4 		$91K Hold
19,411
– – ﹤0.01% 4071
2020
Q3 		$66K Hold
19,411
– – ﹤0.01% 3975
2020
Q2 		$57K Buy
+19,411
New +$66.9K ﹤0.01% 3959

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management's SMMT Position: Q2 2026 in Review

Geode Capital Management increased its Summit Therapeutics (SMMT) stake by 3.4% in Q2 2026, buying an estimated $1.98M and bringing the position to 3,427,263 shares worth $50M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Geode Capital Management first reported a position in SMMT in Q2 2020 and has held it in 25 quarters since. The position peaked at $67.9M in Q3 2024. 224 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Geode Capital Management held 3,427,263 shares of Summit Therapeutics worth $50M as of Q2 2026.
  • Geode Capital Management bought 111,409 Summit Therapeutics shares in Q2 2026, an estimated $1.98M.
  • Summit Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1628 holding.
  • Geode Capital Management first reported a position in Summit Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Geode Capital Management's Summit Therapeutics position peaked at $67.9M in Q3 2024.
  • 224 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.